Lerner Lorena Raquel 4

What Happened

• Lorena Lerner (listed as Lerner Lorena Raquel), Chief Scientific Officer of Keros Therapeutics (KROS), received a grant/award of 75,000 derivative shares on February 24, 2026. The Form 4 reports an acquisition at $0.00 per share (transaction code A), i.e., an equity award/option rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-24; Form 4 filed: 2026-02-26 (filed timely).
• Transaction type: Grant/Award of a derivative instrument (code A); reported price $0.00; reported cash value $0 in the filing.
• Shares involved: 75,000 shares.
• Shares owned after transaction: Not disclosed in this filing.
• Vesting/other footnote: One-fourth of the shares subject to the option vest on February 24, 2027; the remaining shares vest in twelve substantially equal quarterly installments thereafter, subject to continued service.
• No 10b5-1 plan, tax-withholding, or late-filing indication noted in the reported filing.

Context

• This was a standard equity award/option grant as part of compensation and retention—these awards typically vest over time and do not represent an immediate market purchase or sale. Such grants can dilute existing shares over time and align executive incentives with company performance, but they do not, by themselves, signal a near-term buying or selling decision.